Cerebrolysin in Hong Kong
Improves Motor and Cognitive Functions in Stroke and TBI
Improves Cognitive performance in demantiac
Helps prevent Cognitive decline after stroke and TBI
What is cerebrolysin
Cerebrolysin is a multifaceted peptide-based drug with diverse pharmacological properties. It is used to help treating a variety of acute and chronic central nervous system (CNS) disorders. Cerebrolysin has been shown to modulate two key signaling pathways:
- Neurotrophic Factor (NTF) Pathway: This pathway helps maintain, protect, and restore neuronal networks, ensuring proper brain function.
- Sonic Hedgehog (Shh) Signaling Pathway: This pathway regulates the development of organs, including the organization and structure of the brain.
By targeting these critical signaling cascades, Cerebrolysin aims to provide neuroprotective and restorative effects in the treatment of various CNS conditions.
Therapeutic Areas
Stroke
Disturbed or interrupted
blood flow in the brain
Traumatic Brain Injury
Damage to neuronal structures and brain substances
Neurocognitive Disorders
Neurodegenerative processes kill neurons and disrupt neuronal networks
Pathophysiological Challenges:
- Disruption of the brain’s regulatory processes including those controlled by neurotrophic factors (NTFs)
- Local deprivation of NTFs in the affected brain tissue
Acute Phase
Rehabilitation Phase
Traumatic Brain Injury
Treatment Prevention
After primary damages the affected part of the brain develops a secondary pathological cascade
- Uncontrolled apoptosis
- Excessive neuroinflammation
- Formation of free radicals
- Excitotoxcity
- Neuronal Dysregulation
- Neurodegeneration
A multi-modal drug for acute and post-acute neurological disorder
Boosts Faster Recovery
- Combination therapy Cerebrolysin with rtPA results in faster recovery than rtPA alone.
- Cerebrolysin shifts the day 90 responder rate forward to day 10
- Early add-on of cerebrolysin to reperfusion therapy reduces risk of hemorrhagic transformation by -40%
IMproves Motor Functions
- Significant improvement of upper limb motor functions by +88% with structured rehabilitation
- Recovery was faster and showed long-term effects in Cerebrolysin group
Effective treatment after TBI
Results from CAPTAIN II trial
- Treatment with Cerebrolysin shows improvement of global outcome in moderate-severe TBI patients at 90 days as compared to placebo
- 6 out of 7 single outcome scales showing the superiority of Cerebrolysin already on day 10
In the meta-analysis of the CAPTAIN Trail Series by Vester et.al
- 70.5% of Cerebrolysin patients recover from depression after TBI
- +31% more Cerebrolysin patients show normalization in HADS depression score vs placebo
Cerebrolysin Inclusion in Evidence-Based
Review of moderate to severe Acquired Brain Injury
Conclusion:
- There is level 1b evidence that Cerebrolysin is an effective therapy that may improve attentional function for individuals living with moderate to severe TBI.
Improves cognitive performance in Alzheimer's Disease (AD)
- Cerebrolysin 10ml in combination with donepezil was more effective than monotherapy in mild-to-moderate AD patient
- The combination of cerebrolysin with Donepezil is a sage treatment option
- In a study to access the。ffect Cerebrolysin inpatient with more advanced forms of AD
- Patients treated with Cerebrolysin were improved significantly, resulting in a treatment difference of 4.1 points (p<0.001) compared to long term beneficial effects on Cognition
Improves cognitive functions in vascular dementia (VaD)
- In a 24-week, randomized, double-blind, placebo-controlled study in VaD patient
- ADAS-cog+ in patients with Cerebrolysin is significantly improved at week 24 (p<0.0001)
- The CIBIC+ assessement shows a signifant improvement in。erebrolysin group(75.3% vs 37.4% in placebo group)
Cerebrolysin is safe and well tolerated
ACcording to EMA Classification, cerebrolysin is in the safe category.
A comprehensive safety meta-analysis confirms the safety profile for patients treated with Cerebrolysin after acute ischemic stroke, as compared to placebo.
Clinical Benefits for Patients
Treatment of neurological disorders with Cerebrolysin helps to increase the quality of life for patients.
Stroke
- Early Recovery
- Improvement of motor functions
- Regained independence
- Increased quality of life
- Improvement of cognitive functions
- higher survival ratre
Traumatic Brain Injury
- Effective treatment after TBI
- Save lives
- Early recovery
- Better Quality of life
- Improvement and concentration
Neurocognitive Disorders
- Improvement of cognitive performance
- Higher quality of life
- Prolong active an independent life
- Prevention of behavioural disorders
References
Research on Cerebrolysin and Neuroprotective Effects:
- Guekht AB, et al. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases. 2011;20(4):310–318.
- Alvarez XA, et al. Cerebrolysin in mild-to-moderate Alzheimer’s disease: a meta-analysis of randomized controlled clinical trials. Dementia and Geriatric Cognitive Disorders. 2015.
- Vestergaard K, et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: Results of a 3-month extension study. Journal of the Neurological Sciences. 2010;299(1-2):179–183.
Research on Cerebrolysin, Cognitive Function and Brain Function:
- Damulin IV, Koberskaia NN, Mkhitarian EA. Effects of Cerebrolysin on moderate cognitive impairments in cerebral vascular insufficiency: a clinical-electrophysiological study. Neuroscience and Behavioral Physiology. 2008;38:537–543.
- Damulin IV, Koberskaia NN, Mkhitarian EA. The effect of Cerebrolysin on moderate cognitive impairment in cerebral vascular insufficiency. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2007.
- Clinical efficacy of Cerebrolysin in cognitive impairment: evidence from randomized controlled trials and clinical studies.
Research on Cerebrolysin, Neurotrophic Effects and Neuroplasticity:
- Alvarez XA, et al. Cerebrolysin: a neurotrophic peptide preparation with neuroprotective and neuroplasticity-promoting properties. Neuroscience Research.
- Masliah E, et al. Neurotrophic factors and neuroplasticity in neurodegenerative disorders: implications for therapeutic approaches. Neuroscience & Biobehavioral Reviews.
- Cerebrolysin and its effects on neuronal survival, synaptic plasticity and cognitive function: experimental and clinical evidence.
Research on Cerebrolysin, Stroke Recovery and Neural Repair:
- Lang W, et al. Safety and efficacy of Cerebrolysin in acute ischemic stroke: a randomized controlled trial. Journal of Neural Transmission. 2010.
- Muresanu DF, et al. Neuroprotective and neurorestorative effects of Cerebrolysin in stroke rehabilitation. Journal of Stroke and Cerebrovascular Diseases.
- Cerebrolysin in Patients with Traumatic Brain Injury: Systematic Review and Meta-Analysis. Brain Sciences. 2023.
Research on Cerebrolysin Safety and Clinical Applications:
- Cerebrolysin in mild-to-moderate Alzheimer’s disease: a meta-analysis of randomized controlled clinical trials. Dementia and Geriatric Cognitive Disorders. 2015.
- Cerebrolysin for vascular dementia. Cochrane Database of Systematic Reviews. 2019.
- Antal A, et al. Low intensity transcranial electric stimulation: Safety, ethical, legal regulatory and application guidelines. Clinical Neurophysiology. 2017.